GlaxoSmithKline's Witty Plays Down Impact Of U.S. Health Care Reform
Health care reform in the U.S. will not have a significant impact on GlaxoSmithKline's performance in 2010, the company's CEO Andrew Witty told analysts during a first-quarter earnings call on April 28
You may also be interested in...
SEOUL - GlaxoSmithKline is paying KRW142.9 billion ($128.7 million) to acquire a 9.9 percent stake in South Korea's leading Dong-A pharmaceutical and OTC company. The strategic alliance should help GSK gain market share in the rapidly growing Korean pharmaceutical market
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011